direct factor Xa inhibitors

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

atrial fibrillation

apixaban
AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting 14%-21%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-30%-11%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
edoxaban
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -20%-8%
rivaroxaban
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting 4%-8%

cardiovascular prevention

rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias - 8100%

thrombosis prevention

apixaban
ADVANCE 3, 2010    NCTapixabanenoxaparinhip surgeryLow risk of bias suggesting22%199%
ADVANCE 2, 2010      NCTapixabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting-35%+Infini%
APROPOS 2.5mg, 2007    NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias negative+Infini%
ADVANCE-1, 2008      NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting-50%0%
edoxaban
STARS J-V    NCTedoxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
rivaroxaban
RECORD 1, 2008      NCTrivaroxabanenoxaparinhip surgeryLow risk of bias suggesting202%-2%
RECORD 3, 2008    NCTrivaroxabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting19%-100%
ODIXa-HIP 10mg, 2006   rivaroxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
RECORD 2, 2008    NCTrivaroxaban (long duration)enoxaparin (short duration)hip surgeryLow risk of bias suggesting0%-66%
ODIXa-KNEE, 2005   rivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias negative-100%
RECORD 4, 2009    NCTrivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting147%-34%

venous thrombosis

ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting20%-14%